Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.72 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.67 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.62 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11983140 | 1.00 | CYP19A1 (0.72) | CYP19A1HMOX1CYP51A1CYP11B1CYP11B2 | |
| SCHEMBL10974565 | 0.86 | CYP19A1 (0.58) | CYP19A1HMOX1CYP51A1ADRA2C | |
| SCHEMBL10932073 | 0.85 | CYP19A1 (0.73) | CYP19A1HMOX1CYP51A1CYP11B1ADRA2C | |
| SCHEMBL11756428 | 0.84 | CYP19A1 (0.53) | CYP19A1HMOX1CYP51A1CYP11B1CYP11B2 | |
| SCHEMBL7562437 | 0.84 | CYP19A1 (0.72) | CYP19A1HMOX1CYP51A1 | |
| SCHEMBL10197408 | 0.84 | HMOX1 (0.91) | CYP19A1HMOX1CYP51A1CYP11B1CYP11B2 | |
| SCHEMBL10816487 | 0.84 | HMOX1 (0.91) | CYP19A1HMOX1CYP51A1CYP11B1CYP11B2 | |
| SCHEMBL11266884 | 0.84 | CYP19A1 (0.72) | CYP19A1HMOX1CYP51A1CYP11B1CYP11B2 | |
| SCHEMBL6299999 | 0.84 | CYP19A1 (0.72) | CYP19A1HMOX1CYP51A1 | |
| SCHEMBL6299346 | 0.83 | CYP19A1 (0.71) | CYP19A1HMOX1CYP51A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109320458-B | Diaryl imidazole-containing compound, preparation method and medical application thereof | 中国药科大学 | 2022-05-31 | — | — | CN | disclosed |
| EP-1879873-B1 | NEUROTHERAPEUTIC AZOLE COMPOUNDS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-10-09 | — | — | EP | disclosed |
| US-7598279-B2 | Neurotherapeutic azole compounds | SK HOLDINGS CO., LTD. (KR) | 2009-10-06 | — | — | US | disclosed |
| EP-1879873-A1 | NEUROTHERAPEUTIC AZOLE COMPOUNDS | SK Holdings Co., Ltd. (KR) | 2008-01-23 | — | — | EP | disclosed |
| US-20060258718-A1 | Neurotherapeutic azole compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2006-11-16 | — | — | US | disclosed |
| WO-2006112685-A1 | NEUROTHERAPEUTIC AZOLE COMPOUNDS | SK HOLDINGS CO., LTD. (KR) | 2006-10-26 | — | — | WO | disclosed |
| US-4349556-A | Pesticidally active 1-acyloxy-1-phenyl-2-azolyl-ethanes | BAYER AKTIENGESELLSCHAFT (DE) | 1982-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258718-A1 | Neurotherapeutic azole compounds | CHRNA10, CHRNA4, CHRNA3 | CYP19A1 434/4885HMOX1 1965/4885CYP51A1 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.